Aptalis Pharmaceutical Technologies Sponsors 2012 Controlled Release Society's Young Investigator Award at 39thAnnual Meeting and Exposition
Published: Jul 06, 2012
2012 CRS Young Investigator Award
Aptalis Pharmaceutical Technologies, co-sponsor of the 2012 CRS Young Investigator Award, joins the Controlled Release Society in recognizing Cory Berkland, M.S., Ph.D. as the recipient of the 2012 CRS Young Investigator Award at the Society’s Annual Meeting & Exposition. Dr. Berkland is a professor in the Department of Chemical and Petroleum Engineering and in the Department of Pharmaceutical Chemistry at the University of Kansas, U.S.A. He received M.S. and Ph.D. degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois at Urbana-Champaign and a B.S. degree in chemical engineering from Iowa State University in Ames. His lab studies colloids, polymers, and biomaterials. Professor Berkland is a co-founder of Orbis Biosciences and Savara Pharmaceuticals.
The Young Investigator’s Award recognizes a CRS member, who has made outstanding contributions in the science of controlled release, and be 40 years of age or younger on December 31, 2011.
CRS Annual Meeting & Exposition
Aptalis Pharmaceutical Technologies’ two poster presentations, conducted in collaboration with the University of Genova, Italy are:
• A Hydrophilic Matrix Generated by Direct Compression and Thermal Treatment: Application in Press-Coating. Poster session #2, Tuesday, July 17, 9:30 – 10:30 a.m. at Poster Board #480
• A New Hydrophilic Bioadhesive Matrix for Controlled Drug Release Generated In Direct Compression Tablets by Thermal Treatment: Mechanism Elucidation. Poster session #3, Tuesday, July 17, 3:00 – 4:00 p.m. at Poster Board #481 Meeting participants are invited to visit Aptalis Pharmaceutical Technologies at Booth #209 and attend the above poster presentations.
About Aptalis Pharmaceutical Technologies
Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies, offers a broad portfolio of oral drug delivery technology platforms: Customized Drug Release, Bioavailability Enhancement, and Taste Masking for ODT’s (orally disintegrating tablets) and other dosage forms. Together, these technology platforms combined with licensing, manufacturing, and R&D capabilities enable Aptalis Pharmaceutical Technologies to produce customized drug formulation solutions for partners across a range of dosage forms and therapies with high patient acceptability. Aptalis Pharmaceutical Technologies develops and manufactures products for its partners, as well as support the drug development process for the Aptalis Pharma pipeline and portfolio of products. For more information about Aptalis Pharmaceutical Technologies, visit www.AptalisPharmaTech.com
Aptalis Pharma Inc. is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis, formed from the recent combination of Axcan Pharma and Eurand, has manufacturing and commercial operations in the United States, the European Union and Canada, and its products include ZENPEP®, CANASA®, CARAFATE®, PYLERA®, LACTEOL®, DELURSAN®, PANZYTRAT® and SALOFALK®. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and ! !others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit www.aptalispharma.com.
Erin O’Brien, Director of Marketing
Aptalis Pharmaceutical Technologies